Alprolix
eftrenonacog alfa · Swedish Orphan Biovitrum AB (publ)
ORPHAN AUTHORISED IN THE EUWhat Alprolix is used for
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Alprolix
- Active substance
- eftrenonacog alfa
- Disease area
- Hemophilia B
- Medicine group
- Vitamin K and other hemostatics;Blood coagulation factors
- ATC code
- B02BD04
- Marketing authorisation holder
- Swedish Orphan Biovitrum AB (publ)
- Authorised in the EU since
- 2016
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Alprolix used for?
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
What is the active substance in Alprolix?
Alprolix contains eftrenonacog alfa.
Who makes Alprolix?
The EU marketing authorisation holder is Swedish Orphan Biovitrum AB (publ).
Is Alprolix an orphan medicine?
Yes. Alprolix is designated an orphan medicine in the EU, for a rare disease (Hemophilia B).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU